early-stage hypertrophic cardiomyopathy

Valsartan, an angiotensin II receptor blocker drug, delayed disease progression and improved cardiac structure and function in patients with early-stage hypertrophic cardiomyopathy, according to results from a recent clinical trial published in Nature Medicine. This is the first time we have identified a treatment that may actually impact the underlying disease process, as opposed to